Supreme Court confirms that generic drug manufacturers can challenge brand-name use-code descriptions in patent litigation

by Sheppard Mullin Richter & Hampton LLP

[authors: Nagendra Setty and Bill Blonigan]

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S 566 U.S. ___, 132 S. Ct. 1670 (Apr. 17, 2012)

The Hatch-Waxman Act

Congress designed the Hatch-Waxman Act (codified at 21 U.S.C. § 355(b), (j), (l) and 35 U.S.C. §§ 156, 271, and 282) to inspire medical innovation by giving medical-device and pharmaceutical patent owners a more fruitful patent term while providing follow-on manufacturers to more quickly market their products once medical patents expire. Unlike other products, advanced medical devices and drugs must be FDA approved. These products can’t be marketed until proven sufficiently safe and effective through tests and clinical trials. FDA approval is expensive and time consuming. But it’s more than a matter of time and money. Medical innovators—especially drug developers—face the significant risk that a potential product will not live up to its promise.

Patents generally provide a time-limited monopoly that’s meant to reward innovation. But to reward the clinical-trial gamble, the Hatch-Waxman Act offers an extended patent monopoly through Patent Term Extension to medical-device and drug patent owners (also called brand-name manufacturers, or brands) that commercialize innovative medical products. The extended patent term helps offset the patent’s wasted youth, which was spent awaiting FDA approval instead of generating sales revenue under a patent monopoly. But a longer patent term means a longer wait for me-too manufacturers (also called generic manufacturers, or generics) that must wait out the extended patent term to sell the patented product. For generics, Congress leveled the playing field by allowing them to piggyback on brand-name manufacturers’ clinical-trial results. This allows them to bring generic products to market faster and less expensively. The concept is simple enough. But the Hatch-Waxman Act is possibly the gnarliest thicket of patent legislation ever enacted.

Under Caraco, use codes must coincide with patent scope

In Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, the Supreme Court interpreted a portion of the Hatch-Waxman Act that deals with so-called section viii statements or, more specifically, use codes and carve-out drug labeling. Brand-name manufacturers must file a use code that describes what uses of the drug are patented and, therefore, off limits to generics. The patent owner drafts the use code, and the FDA assumes, without question, that it is accurate.

A generic can sell the drug despite the patent if it carves out a product label that doesn’t instruct users to practice any method described in the use code as long as: (1) a brand’s patent covers only some of the drug’s possible uses and (2) the drug compound itself is not patented.

Problems can arise when patent owners—like Novo Nordisk in Caraco—draft use codes that extend to non-patented uses of the drug and thus prevent competitors from entering the market by virtue of patent rights that could not otherwise provide such a broad monopoly.

Caraco wanted to market the diabetes drug repaglinide, the generic name of Novo Nordisk’s Prandin. Repaglinide is FDA approved to treat diabetes in three ways: (1) by itself, (2) combined with either another drug, metformin, and (3) combined with one of a class of drugs, called thiazolidinediones (TZDs). Because Novo Nordisk’s patent claimed only the second use, Caraco believed that it should have been able to carve out a label covering only the other two uses. But just after Caraco submitted its carve-out label to the FDA, Novo Nordisk broadened its use code to state that its patent covered all three methods. Accordingly, the FDA refused to approve Caraco’s generic drug. When Novo Nordisk sued Caraco for patent infringement, Caraco filed a counterclaim seeking to force Novo Nordisk to change its use code by removing reference to the two unpatented methods. Novo Nordisk argued that the Hatch-Waxman Act did not allow such a counterclaim.

The Supreme Court disagreed. Construing the relevant portions of the Hatch-Waxman Act, the Court reasoned that within the literal and policy context of the statute, it would make no sense to allow patentees to block unpatented treatment methods by filing inaccurate use codes with the FDA. “Congress meant (as it usually does) for the provision it enacted to fit within the statutory scheme—here, by facilitating the approval of non-infringing generic drugs under section viii.” Caraco, 566 U.S. ___, slip op. at 15 (construing 21 U.S.C. § 355(j)(5)(C)(ii)(I)).

Caraco’s reasoning is relevant to medical-device patents

While Caraco involved a portion of the Hatch-Waxman Act that directly affects only drug companies, the Supreme Court’s reasoning and statutory construction could also affect medical-device companies. In Eli Lilly & Co. v. Medtronic, Inc., 496 U. S. 661 (1990), the Supreme Court interpreted the Act—formally titled, The Drug Price Competition and Patent Term Restoration Act of 1984—broadly, holding that it exempted from patent infringement acts done in pursuit of obtaining FDA approval by not only drug companies, as the Act’s formal name obviously suggests, but also medical-device companies. Id. at 672–73. The Court recognized that because Hatch-Waxman was a literal balancing Act, it would be unfair if medical-device patentees could enjoy the advantage of an extended patent term under 35 U.S.C. § 156 without suffering the disadvantage of a patent-infringement safe harbor (under 35 U.S.C. § 271(e)(1)) for competitors seeking FDA approval. Accordingly, there is a strong argument that the Hatch-Waxman Act balances incentives for drugs and medical devices consistently.

Just as Caraco concerned the unfairness of broadening a drug patent’s reach by crafting overbroad use codes, medical-device patents can be effectively broadened through arguably overbroad Patent Term Extension. In Advanced Cardiovascular Sys., Inc. v. Medtronic, Inc., No. C95-03577-DLJ, 2008 U.S. Dist. LEXIS 88892 (N.D. Cal. Oct. 21, 2008) (ACS), for example, the asserted patent claimed a rapid-exchange stent-delivery catheter. The patented catheter was one of four components in a drug-coated-stent kit. In the ACS court’s view, the delivery catheter played only a trivial role in delivering treatment—which the court compared to a spoon that delivers medicine to a patient’s mouth—and the focus of the FDA’s review was on the drug-coated stent. Further, while the Hatch-Waxman Act only allows Patent Term Extension based on the first premarket-approval (PMA) of the patented product, the patented catheter had already been used in at least 100 other FDA-approved devices. To extend the term of the delivery-catheter patent based on the FDA’s review of the hundred-and-first product that, only by “happenstance,” used the patented technology “would work a thorough distortion of Hatch-Waxman,” said the court. Id. at *36.

Nevertheless, and controversially, the Patent Office extended the term of the delivery-catheter patent. Critics, like the ACS court, argue that by so liberally extending the life of medical-device patents—when FDA review did not delay commercialization of the patented technology—the Patent Office is missing the point of the Hatch-Waxman Act’s Patent Term Extension scheme—to make up for market time lost during the PMA process—and extending the lives of too many patents. Medical-device manufacturers seeking to challenge the government’s liberal policy can now cite Caraco, in addition to Eli Lilly and ACS, for the proposition that the Hatch-Waxman Act should be interpreted to fit within the statutory balancing act—not to reward happenstance.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sheppard Mullin Richter & Hampton LLP | Attorney Advertising

Written by:

Sheppard Mullin Richter & Hampton LLP

Sheppard Mullin Richter & Hampton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.